Form 4: Revelation Biosciences CEO Receives Stock Grant
Insider Transaction (Form 4)
James Rolke, Chief Executive Officer and a Director of Revelation Biosciences, Inc., received 208,076 shares of common stock on August 17, 2026.
Summary
- Grant/award: acquired 208,076 Common Stock on August 17, 2026; holds 422,814 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
James Rolke — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Grant/award | Common Stock | 208,076 | — | — | 422,814 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Grant/award (208,076 shares) |
Keywords
insider transaction, Form 4, REVB, REVELATION BIOSCIENCES, INC., neutral, James Rolke
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.